X4 Pharmaceuticals Reports 91% Revenue Decline in Q1 2026, Focuses on Clinical Trials

X4 Pharmaceuticals, Inc. reported a significant decline in financial performance for the first quarter of 2026, with total revenue of $2.7 million, a decrease of approximately 91% compared to $28.8 million in the same period of 2025. The drop in revenue was primarily attributed to a substantial reduction in license and other revenue, which fell from $27.9 million to $0.2 million, reflecting the absence of significant milestone payments from a licensing agreement with Norgine Pharma UK Ltd. Product revenue, however, showed growth, increasing to $2.5 million from $0.9 million, driven by a higher number of patients prescribed the company's drug, XOLREMDI® (mavorixafor).

The company's operating expenses also decreased, totaling $23.0 million for the quarter, down from $38.2 million in the prior year. This reduction was largely due to lower general and administrative costs, which fell by $8.1 million, and a decrease in research and development expenses, which dropped by $3.0 million. The net loss for the quarter was $20.2 million, compared to a net income of $0.3 million in the first quarter of 2025, resulting in a net loss per share of $0.16.

In terms of strategic developments, X4 Pharmaceuticals continues to focus on its pivotal Phase 3 clinical trial, known as the 4WARD trial, for mavorixafor, which is aimed at treating chronic neutropenic disorders. The trial is expected to enroll up to 176 patients, with full enrollment anticipated by the end of the third quarter of 2026. The company has also received Fast Track designation from the U.S. Food and Drug Administration for mavorixafor, which is a key component of its long-term strategy.

Operationally, X4 Pharmaceuticals reported a cash position of $233.7 million as of March 31, 2026, which the company believes will be sufficient to fund operations for at least the next 12 months. The company has undergone significant restructuring, resulting in a 65% reduction in employee headcount, aimed at aligning resources with its strategic focus. As of the end of the first quarter, the company had 94.3 million shares outstanding, reflecting an increase from the previous quarter due to the exercise of prefunded warrants.

Looking ahead, X4 Pharmaceuticals acknowledges the challenges it faces, including the need for additional capital to fund ongoing operations and the uncertainty surrounding the market acceptance of its products. The company is committed to advancing its clinical programs and maintaining its focus on the commercialization of mavorixafor, while also exploring opportunities for further product development and potential partnerships.